Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of AbbVie Inc.
The lawsuit seeks to recover losses for shareholders who purchased AbbVie between April 30, 2021 and August 31, 2021.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until June 6, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
According to a filed complaint, AbbVie Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887